

ABIOMED INC  
Form 4  
February 17, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**TERMEER HENRI A**

(Last) (First) (Middle)

**C/O ABIOMED, INC., 22 CHERRY HILL DRIVE**

(Street)

**DANVERS, MA 01923**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**ABIOMED INC [ABMD]**

3. Date of Earliest Transaction (Month/Day/Year)  
**02/15/2011**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D) Code V Amount (D) Price			
Common Stock, \$0.01 par value					60,100	D	
Common Stock, \$0.01 par value	02/15/2011		S	14,605 D	\$ 13.4656 1,856,626	I	by Genzyme Corporation (3)
Common Stock, \$0.01 par value	02/16/2011		S	300 D	\$ 13.4617 1,856,326	I	by Genzyme Corporation (3)

Edgar Filing: ABIOMED INC - Form 4

Common Stock, \$0.01 per value	02/16/2011	S	7,946	D	\$ 13.3145 (8)	1,848,380	I	by Genzyme Corporation (3)
---	------------	---	-------	---	----------------------	-----------	---	----------------------------------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) <sup>(1)</sup>	\$ 19.69					08/09/2001 <sup>(2)</sup>	08/09/2010	Common Stock	5,000
Stock Option (right to buy) <sup>(1)</sup>	\$ 18.4					08/08/2002 <sup>(2)</sup>	08/08/2012	Common Stock	5,000
Stock Option (right to buy) <sup>(1)</sup>	\$ 4.71					08/06/2003 <sup>(2)</sup>	08/06/2013	Common Stock	5,000
Stock Option (right to buy) <sup>(1)</sup>	\$ 5.15					08/13/2004 <sup>(2)</sup>	08/13/2014	Common Stock	5,000
Stock Option (right to buy) <sup>(4)</sup>	\$ 10.41					08/11/2005 <sup>(2)</sup>	08/11/2014	Common Stock	8,000

Stock Option (right to buy) <sup>(4)</sup>	\$ 10.06	08/09/2006 <sup>(2)</sup>	08/10/2015	Common Stock	8,000
Stock Option (right to buy) <sup>(4)</sup>	\$ 13.21	08/08/2007 <sup>(2)</sup>	08/09/2016	Common Stock	8,000
Stock option (right to buy) <sup>(4)</sup>	\$ 12.69	08/13/2008 <sup>(2)</sup>	08/08/2017	Common Stock	8,000
Stock Option (right to buy) <sup>(5)</sup>	\$ 18.63	08/12/2009 <sup>(2)</sup>	08/13/2018	Common Stock	8,000
Stock Option (right to buy) <sup>(5)</sup>	\$ 7.67	08/11/2010 <sup>(2)</sup>	08/12/2019	Common Stock	12,000
Stock Options (right to buy) <sup>(5)</sup>	\$ 9.99	08/10/2011	08/11/2020	Common Stock	12,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TERMEER HENRI A C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923	X			

## Signatures

/s/ Ian W. McLeod (by power of attorney) 02/17/2011

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors.
  - (2) This option becomes exercisable in full on the date set forth in Table II, Column 6.

## Edgar Filing: ABIOMED INC - Form 4

- The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the
- (3) reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purposes. The reporting person is the Chief Executive Officer of Genzyme Corporation.
  - (4) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
  - (5) Grant to reporting person of option to buy shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.

(6) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$13.45 and \$13.49. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$13.45 and \$13.485. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$13.30 and \$13.35. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.